Applied Intelligence for Imaging
Transforming data to actionable insights
Mammography Insights provides a multi-vendor mammography practice with a summary of radiation dose, utilization and standardization metrics that enable radiology directors, imaging supervisors and clinicians to optimize clinical and operational performance of their assets and practice.
Radiology Operational Effectiveness for RIS/PACS helps identify, prioritize and execute actionable insights to help identify and prioritize improvement opportunities, and drive sustainable change across your enterprise imaging service lines.
Applied Intelligence is the analytics brain that powers GE Healthcare’s applications and devices.
Applied Intelligence is the analytics "brain" powering better clinical, operational and financial outcomes.
Applications utilizing Applied Intelligence can be found across GE Healthcare’s full portfolio of solutions, producing a wide-range of individual software components designed to answer targeted questions or provide specific insights.
All of GE Healthcare’s analytic solutions are built on a common framework; this unified structure ensures that all our cross-modality solutions can talk to each other.
Consulting services are available to augment analytic offerings to ensure the best fit for your organization.
16,000 images per minute are captured on medical devices from GE Healthcare.
CCA Analytics is pilot; X-Ray and Mammo are planned for LA/GA by RSNA; Operations Effectiveness for RIS/PACS is offered as a service currently
1. Centricity Clinical Archive includes the following product components: Centricity Enterprise Archive, Centricity Universal Viewer ZFP, XDS Registry, Centricity Clinical Gateway, NextGate MatchMetrix EMPI, and Lexmark PACS Scan™.
The X-Ray Quality Application and Mammography Insights are currently commercially available in Limited Availability release. The Radiology Operations Effectiveness Analytics is commercially currently commercially available as a service. A commercially released packaged product is planned for Q1 2018. May not be available in all regions.
CCA Analytics is in development and is planned for commercial availability in Q2 2018
Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.